{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:47:26Z","timestamp":1789015646350,"version":"build-2803163510"},"reference-count":33,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Short-term data suggest that stage I\/II NLPHL can be treated with ISRT without a negative impact on disease-free survival.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018029140","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T16:47:12Z","timestamp":1556556432000},"page":"1356-1367","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3982-3664","authenticated-orcid":false,"given":"Chelsea C.","family":"Pinnix","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Milgrom","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia;"},{"name":"Department of Haematology, Pathwest Laboratory Medicine, Nedlands, WA, Australia;"},{"name":"Medical School, University of Western Australia, Crawley, WA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian R.","family":"Gunther","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5472-5344","authenticated-orcid":false,"given":"Ethan B.","family":"Ludmir","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine F.","family":"Wogan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-3629","authenticated-orcid":false,"given":"Raphael E.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-8697","authenticated-orcid":false,"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Rich","sequence":"additional","affiliation":[{"name":"Orlando Regional Medical Center, Orlando, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"issue":"3","key":"2019112008020698200_B1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019112008020698200_B2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019112008020698200_B3","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/leu.2015.321","article-title":"Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group","volume":"30","author":"Eichenauer","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2019112008020698200_B4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019112008020698200_B5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2019112008020698200_B6","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2019112008020698200_B7","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019112008020698200_B8","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"2019112008020698200_B9","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019112008020698200_B10","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"2019112008020698200_B11","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the Randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"2019112008020698200_B12","author":"Fuchs","year":"2018"},{"issue":"26","key":"2019112008020698200_B13","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019112008020698200_B14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019112008020698200_B15","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"issue":"17","key":"2019112008020698200_B16","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"key":"2019112008020698200_B17","author":"Swerdlow","year":"2017"},{"issue":"10","key":"2019112008020698200_B18","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"26","key":"2019112008020698200_B19","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"issue":"27","key":"2019112008020698200_B20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2019112008020698200_B21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: issues in delineating the radiation field in Hodgkin\u2019s disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"issue":"4","key":"2019112008020698200_B22","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2019112008020698200_B23","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"282","key":"2019112008020698200_B24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"2019112008020698200_B25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","article-title":"Review of survival analyses published in cancer journals","volume":"72","author":"Altman","year":"1995","journal-title":"Br J Cancer"},{"issue":"6","key":"2019112008020698200_B26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"issue":"9","key":"2019112008020698200_B27","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.1997.15.9.3060","article-title":"Clinical presentation and outcome in lymphocyte-predominant Hodgkin\u2019s disease","volume":"15","author":"Bodis","year":"1997","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019112008020698200_B28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA Lymphoma Group guidelines","volume":"88","author":"Girinsky","year":"2008","journal-title":"Radiother Oncol"},{"issue":"3","key":"2019112008020698200_B29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"issue":"1","key":"2019112008020698200_B30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"issue":"7","key":"2019112008020698200_B31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2019112008020698200_B32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ijrobp.2008.09.049","article-title":"Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin\u2019s lymphoma","volume":"74","author":"Haas","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"2019112008020698200_B33","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/9\/1356\/784600\/advances029140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/9\/1356\/784600\/advances029140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T08:02:26Z","timestamp":1574236946000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/9\/1356\/247084\/Favorable-outcomes-with-deescalated-radiation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018029140","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]}}}